Revive Therapeutics Ltd (RVVTF)

[ReikoBlack]

I see a pattern. Does anyone else see it?

Press Release – September 18, 2024: Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
“The research study is progressing and is expected to be now completed in October 2024.”

Press Release – October 31, 2024: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
“The research study is progressing and is now expected to be completed with final results by the end of calendar 2024."

Press Release – February 3, 2025: Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
“The research study is progressing and is expected to be now completed in February 2025.”

Press Release – May 12, 2025: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
“After recent discussions with the DRDC, the research study on Bucillamine is now set to conclude by June 2025,”

Press Release – June 26, 2025: Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
“After recent discussions with the DRDC, the research study on Bucillamine is now set to conclude by September 2025.”

Press Release – July 8, 2025: Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
“The research study with Bucillamine is slated for continuation through September 2025,”

Press Release – December 15, 2025: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
“After recent discussions with the DRDC, the research study on Bucillamine is expected to conclude with results in January 2026.”

Press Release – March 11, 2026: Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
“Following recent discussions with the DRDC, the Bucillamine research study is expected to conclude with results shortly.”